secwatch.observer — SEC 8-K summary
======================================

Issuer:     Serina Therapeutics, Inc. (SER)
CIK:        0001708599
Form:       8-K
Filed at:   2024-08-09T23:59:59+00:00
Accession:  0001493152-24-030996
Event type: earnings
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Serina Therapeutics reports Q2 net income $5.2M but warns of going concern doubt
--------------------------------------------------------------------------------

- Net income $5.2M ($0.61 basic EPS) includes $9.3M non-cash warrant revaluation; operating loss $3.8M.
- Cash and restricted cash $6.1M at June 30; $11.2M owed to Juvenescence; substantial doubt about continuing as going concern.
- Research and development expenses $1.6M (+$1.1M YoY); G&A $2.3M (+$1.8M YoY) partly from Merger costs.
- Partnered with Enable Injections to develop SER-252 (POZ-apomorphine) for Parkinson's; IND planned for 2025.
- Appointed Dr. Srini Tenjarla as SVP of CMC & Formulation; presented POZ-lipid immunogenicity data.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1708599/000149315224030996/0001493152-24-030996-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1708599/000149315224030996/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-030996

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer